Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.

Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging.

We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic disease and local recurrence in patients with BCR after RP.

Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group.

Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level at BCR, and Gleason score (p = 0.0031).

Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.

Cancer biomarkers : section A of Disease markers. 2016 Jun 07 [Epub ahead of print]

Michael O Koch, Jane S Cho, Hristos Z Kaimakliotis, Liang Cheng, Zaina Sangale, Michael Brawer, William Welbourn, Julia Reid Mstat, Steven Stone

Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA., Myriad Genetics, Inc. Salt Lake City, UT, USA., Myriad Genetics, Inc. Salt Lake City, UT, USA., Myriad Genetics, Inc. Salt Lake City, UT, USA., Myriad Genetics, Inc. Salt Lake City, UT, USA., Myriad Genetics, Inc. Salt Lake City, UT, USA.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe